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INTRODUCTION
Helicobacter pylori (H. pylori) infection
affects approximately half of the world’s
population. Unless eradicated, it remains
in the stomach throughout life. After
1983, discovery of H. pylori as persis-
tent resident of gastric mucosa, changed
the traditional thoughts and perspectives
regarding (i) having sterile stomach life-
long, (ii) infectious potential links exis-
tence with various extra gastric disor-
ders, and (iii) ongoing researches on H.
pylori-induced diseases (1). Undeniably,
colonization with pathogenic H. pylori
results in severe gastroduodenal disorders.
H. pylori is well-recognized as an estab-
lished causative agent associated with a
wide variety of upper gastroduodenal dis-
eases ranged from a chronic gastritis to
gastric cancer. Surprisingly, gastric colo-
nization with H. pylori induces superfi-
cial gastritis in all infected individuals,
while only a minority develops to severe
symptomatic diseases (2). Notably, ratio-
nale underlying this unique distribution of
diseases is driven by a sophisticated and
mysterious interplay between H. pylori and
its host. Broadly defined, the certain pat-
tern of H. pylori-induced digestive disease
is strongly influenced by bacterial virulence
factors which draw the final outcome of
infection (2, 3). It is now firmly estab-
lished that biomarkers allow us for hav-
ing an early diagnosis and prediction of
medical conditions. Moreover, biomark-
ers provide opportunity to modify current
available protocols to manage the infec-
tion and its associated outcomes (4). In
this case, a biologic biomarker can be used
for early diagnosis of certain digestive dis-
ease (e.g., gastric cancer, duodenal ulcer);
and even identification of high-risk popu-
lation for disease prevention. As such, bio-
markers are becoming increasingly impor-
tant tools in clinical settings. Thus, poten-
tial applications of biomarkers in infec-
tious diseases such as predicting outcomes
would be an interesting area of ongoing
research. With this regard, the search for
relevant biomarkers that diagnose/predict
a clinical condition among the H. pylori-
infected patients is a challenging area of
research. Following several suggested H.
pylori biomarkers for certain digestive dis-
eases over the past years (5–8), still a
biomarker capable of predicting definitive
digestive diseases outcome is lacking for
clinical settings.
DEFINITION AND APPLICATION OF THE
OPINION
In this new opinion, under condition
of identification of complete duodenal
ulcer promoting (dupA) gene, our knowl-
edge about biomarker application in H.
pylori-induced diseases such as duodenal
ulcer and gastric cancer will be influenced
greatly. Accordingly, we propose a logi-
cal and practical opinion that detection of
full length (dupA and its flanking gene)
(Figure 1) H. pylori dupA gene by simple
multiplex PCR assay can be used to pre-
dict digestive diseases outcome and solve
the above-mentioned problems. To exam-
ine H. pylori dupA as biomarker that can
serve as an indicator of the digestive dis-
ease potential, our opinion can be easily be
evaluated in a cohort of population with
different disease groups including gastric
cancer, duodenal ulcer, and gastritis. Fur-
thermore, primer set which can pick whole
dupA gene in addition to both left and right
sides of the dupA gene (Figure 1) would
be preferable to investigate likely involve-
ment of this cluster in determining final
diseases outcome. To date, an actual func-
tion of dupA is still not fully understood.
Moreover, flanking genes to dupA (virB4,
virB8, and virB9) are also not determined.
Strikingly, the opinion stands the best situ-
ation of being confirmed if dupA as part of
(Type 4 secretion system) T4SS can show
in vivo activity.
DISCUSSION
Current opinion would be confirmed by
a finding that dupA is forming T4SS
in combination of those flanking genes.
Indeed, function of flanking genes to dupA
(virB4, 8, and 9) are not determined yet
(Figure 1). Hence, this interesting gap pro-
motes researchers to examine it within a
cohort study. Of note, dupA gene encodes
homologs of virB4 ATPase which current
knowledge found it involved in DNA trans-
fer/uptake. Involvement of T4SS in patho-
genesis of H. pylori is an apparent fact.
Accordingly, current evidences are indicat-
ing on potential role of dupA to form a
functional T4SS. One further step would
be to check those flanking genes in combi-
nation of dupA; an opinion which might
be able to answer those unclear points
regarding dupA after its introduction in
2005 to now (9, 10). Notably, dupA and
its flanking genes are located in plasticity
region (PR) of the H. pylori genome (11).
It is important to point out that the vir
genes exist before and after the region of
the dupA locus and the surrounding six
vir gene homologs (virB8, virB9, virB10,
virB11, virD4, and virD2) are important
in forming a novel putative T4SS (tfs3a).
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FIGURE 1 | Full type IV secretion system (T4SS) in the H. pylori plasticity zone in J99*.
As a result, H. pylori strains containing
full dupA are bound to be virulent due
to the ability of building a complete T4SS.
In a continuous cluster in H. pylori strain
J99, the PR has been reported to range
from jhp0914 to jhp0961 (Figure 1) (12).
In H. pylori genome, PR is an area where
G+C content is lower than that of the rest
(35% compared with 39%), indicating on
variable genes which mostly are virulence
associated (11). Thus, the polymorphism
pattern in this area of PR can be considered
as related with different set of bacterial vir-
ulence. That would be rationally possible
that sequential contribution of these genes
be involved to determine final outcome
of the H. pylori in colonized individuals.
However, this article is first to present this
possibility; an opinion can be promising
if proven after those mentioned in in vivo
tests.
CONCLUSION
This paper is an invitation for having a
different look in to the biomarkers for
digestive diseases. Current opinion encour-
age using H. pylori dupA as a predicting
tool to screen certain types of digestive dis-
eases such as duodenal ulcer and gastric
cancer.
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